CeriBell, Inc. (CBLL) Free cash flow
- Free cash flow · 12 months (USD): Value $-54.72M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -53.67%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-54.72M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-54.03M − $690.00K ≈ $-54.72M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -53.67% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-54.72M ÷ $101.96M × 100 ≈ -53.67% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-54.03M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.82× | Operating cash flow / net income. Period ending 2026-06-30. $-54.03M ÷ $-66.00M ≈ 0.82× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -54.03M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 690.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -54.72M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 101.96M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -66.00M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-54.72M | (m) | $-54.03M | $690.00K | (m) | $101.96M | (m) | $-66.00M | (m) | (m) | -53.67% | 0.82× |
| 2026-03-31 | $-49.45M | (m) | $-48.70M | $744.00K | (m) | $95.07M | (m) | $-60.37M | (m) | (m) | -52.01% | 0.81× |
| 2025-12-31 | $-41.58M | (m) | $-40.81M | $767.00K | (m) | $89.06M | (m) | $-53.41M | (m) | (m) | -46.68% | 0.76× |
| 2025-09-30 | $-40.95M | (m) | $-40.01M | $945.00K | (m) | $82.81M | (m) | $-52.46M | (m) | (m) | -49.45% | 0.76× |
| 2025-06-30 | $-38.60M | (m) | $-37.45M | $1.14M | (m) | $77.42M | (m) | $-49.41M | (m) | (m) | -49.85% | 0.76× |
| 2025-03-31 | $-38.29M | (m) | $-36.90M | $1.39M | (m) | $71.53M | (m) | $-44.71M | (m) | (m) | -53.52% | 0.83× |
| 2024-12-31 | $-36.38M | (m) | $-35.04M | $1.34M | (m) | $65.44M | (m) | $-40.45M | (m) | (m) | -55.59% | 0.87× |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-30.07M | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-30.14M | (m) | $-29.16M | $983.00K | (m) | $45.23M | (m) | $-29.46M | (m) | (m) | -66.65% | 0.99× |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| Streamex Corp. (STEX) | United States | $0.089B | -0.19 |